The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Daniel A. Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J. Borowitz, Michelle M. Le Beau, Clara D. Bloomfield, Mario Cazzola, James W. Vardiman

Research output: Contribution to journalReview article

2031 Citations (Scopus)

Abstract

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.

Original languageEnglish
Pages (from-to)2391-2405
Number of pages15
JournalBlood
Volume127
Issue number20
DOIs
Publication statusPublished - May 19 2016

Fingerprint

Acute Myeloid Leukemia
Health
Neoplasms
Lymphoid Tissue
Biomarkers
Gene expression
Tumors
Tissue
Gene Expression

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., ... Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-2405. https://doi.org/10.1182/blood-2016-03-643544

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. / Arber, Daniel A.; Orazi, Attilio; Hasserjian, Robert; Thiele, Jürgen; Borowitz, Michael J.; Le Beau, Michelle M.; Bloomfield, Clara D.; Cazzola, Mario; Vardiman, James W.

In: Blood, Vol. 127, No. 20, 19.05.2016, p. 2391-2405.

Research output: Contribution to journalReview article

Arber, DA, Orazi, A, Hasserjian, R, Thiele, J, Borowitz, MJ, Le Beau, MM, Bloomfield, CD, Cazzola, M & Vardiman, JW 2016, 'The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia', Blood, vol. 127, no. 20, pp. 2391-2405. https://doi.org/10.1182/blood-2016-03-643544
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-2405. https://doi.org/10.1182/blood-2016-03-643544
Arber, Daniel A. ; Orazi, Attilio ; Hasserjian, Robert ; Thiele, Jürgen ; Borowitz, Michael J. ; Le Beau, Michelle M. ; Bloomfield, Clara D. ; Cazzola, Mario ; Vardiman, James W. / The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. In: Blood. 2016 ; Vol. 127, No. 20. pp. 2391-2405.
@article{51a0788fd03543efb0680e42a3010e09,
title = "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia",
abstract = "The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.",
author = "Arber, {Daniel A.} and Attilio Orazi and Robert Hasserjian and J{\"u}rgen Thiele and Borowitz, {Michael J.} and {Le Beau}, {Michelle M.} and Bloomfield, {Clara D.} and Mario Cazzola and Vardiman, {James W.}",
year = "2016",
month = "5",
day = "19",
doi = "10.1182/blood-2016-03-643544",
language = "English",
volume = "127",
pages = "2391--2405",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

AU - Arber, Daniel A.

AU - Orazi, Attilio

AU - Hasserjian, Robert

AU - Thiele, Jürgen

AU - Borowitz, Michael J.

AU - Le Beau, Michelle M.

AU - Bloomfield, Clara D.

AU - Cazzola, Mario

AU - Vardiman, James W.

PY - 2016/5/19

Y1 - 2016/5/19

N2 - The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.

AB - The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.

UR - http://www.scopus.com/inward/record.url?scp=84974560145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974560145&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-03-643544

DO - 10.1182/blood-2016-03-643544

M3 - Review article

VL - 127

SP - 2391

EP - 2405

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -